source
- FDA clears Vitestro's Aletta, first robotic blood draw device for U.S. clinicsThe U.S. Food and Drug Administration has granted clearance to Vitestro's Aletta, making it the first standalone robotic system approved to draw blood without direct human handling. Aletta can per…
- Leo Pharma to acquire experimental rare-skin disease drug dersimelagon in up to $435 million dealLeo Pharma announced it will acquire the rights to dersimelagon, an experimental oral therapy currently under FDA review, in a transaction that could total up to $435 million in upfront and near‑te…